Solana (HSDT) to Release Earnings on Tuesday

Solana (NASDAQ:HSDT) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($26.50) per share and revenue of $0.14 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Solana Stock Up 3.8%

NASDAQ HSDT opened at $2.19 on Tuesday. The company has a market capitalization of $90.45 million, a price-to-earnings ratio of 0.00 and a beta of 1.08. Solana has a twelve month low of $1.74 and a twelve month high of $366.68. The stock has a fifty day simple moving average of $2.50 and a 200 day simple moving average of $5.97.

Hedge Funds Weigh In On Solana

A number of institutional investors and hedge funds have recently modified their holdings of the business. LPL Financial LLC increased its stake in shares of Solana by 120.1% in the 4th quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock valued at $1,105,000 after acquiring an additional 208,558 shares in the last quarter. Geode Capital Management LLC acquired a new stake in Solana in the fourth quarter worth $1,006,000. State Street Corp bought a new stake in Solana in the fourth quarter valued at $464,000. Cetera Investment Advisers acquired a new position in shares of Solana during the fourth quarter valued at about $347,000. Finally, Marshall Wace LLP bought a new position in shares of Solana during the 4th quarter worth about $195,000. 18.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HSDT. Weiss Ratings reissued a “sell (e+)” rating on shares of Solana in a research note on Thursday, January 22nd. Wall Street Zen raised Solana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Solana presently has an average rating of “Sell”.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.